Jason Haas - Jun 29, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: Jason Haas
Stock symbol
LGND
Transactions as of
Jun 29, 2022
Transactions value $
$0
Form type
4
Date filed
6/30/2022, 06:32 PM
Previous filing
Feb 17, 2022
Next filing
Oct 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1.75K $0.00 1.75K Jun 29, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +5.91K $0.00 5.91K Jun 29, 2022 Common Stock 5.91K $88.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date.